Theravance Biopharma Plunges 27% After Phase 3 Ampreloxetine Trial Failure
Theravance Biopharma's Phase 3 CYPRESS study of ampreloxetine missed primary and secondary endpoints, triggering program wind-down and further data analysis. Shares tumbled 27% as the board initiated a strategic review, cutting half its workforce, taking $5–7M severance and reducing operating expenses by about 60%.
1. Trial Results and Program Wind-Down
Theravance Biopharma’s Phase 3 CYPRESS study of ampreloxetine for neurogenic orthostatic hypotension failed to meet its primary and key secondary endpoints. The company has begun winding down the ampreloxetine program and will perform additional analyses of the dataset, consulting external experts to assess any residual regulatory or commercial value.
2. Strategic Review and Restructuring
The board has accelerated a formal strategic review to maximize shareholder value, engaging advisors to explore potential transactions including a full sale. Organizational restructuring impacts roughly 50% of employees, with one-time severance charges of $5–7 million and an anticipated 60% reduction in operating expenses year-over-year.
3. Financial Impact and Stock Performance
Following the trial setback, shares of Theravance Biopharma dropped about 27%, trading nearer to their 52-week lows. The company maintains a forward P/E of 33.2x and is set to report earnings on March 17, with consensus projecting $0.34 EPS and $41.7 million in revenue.